Managing Clinical Trial Data

In An Era Of Abundant Information

A recent survey conducted by Pharma Intelligence, commissioned by Oracle Health Sciences, reveals the increasing volume and variety of data used in clinical trials has created a new set of data management and governance challenges, resulting in significant and costly problems. Here is a look at the current state of clinical trials, and a preview of the survey findings.

296,245

registered clinical trials as of February 2019



69% INCREASE

since 2015¹

47%

INCREASE in R&D spending at leading biopharma companies from 2011 - 2017²

The industry is investing in more complex trials



86%

More **endpoints** in studies now compared to studies conducted more than a decade ago³

+3 DAYS

Rapid growth in eClinical data volume and diversity has extended the time it takes from last patient, last visit database lock by 3 days, from 2007-2017.

Survey respondents confirmed legacy technologies do not meet the needs of modern day clinical trials



50%

Use more than six different data sources for a typical study

95%

Expend manual
effort to aggregate,
clean and transform
clinical trial data

81%

Identify data governance as the biggest challenge with clinical trial data in meeting regulatory compliance

The survey also uncovered concerns about the future of clinical trials



1/5

Are most concerned about finding resources to manage and clean new data types

1/3

Think by 2024 the **management of mHealth** data will be the most urgent challenge

To learn more about the impact of legacy technologies on clinical trial efficiency, download the research report 'Challenges and Opportunities in Clinical Data Management' at: http://bit.ly/ClinicalDataManagementReport.

ORACLE® Health Sciences

Pharma intelligence

Pharma Intelligence Custom Research on behalf of Oracle Health Sciences | Informa, 2018

Additional Sources:

¹https://web.archive.org/web/20121115085611/https://clinicaltrials.gov/ct2/resources/trends (As of February 03, 2019)

²https://catalyst.phrma.org/phrma-member-companies-rd-investments-hit-record-high-in-2017-71.4-billion-0

3https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5b4de77f758d46a039f157e6/1531832191693/julaug18-pr.pdf
4https://globenewswire.com/news-release/2018/01/09/1286051/0/en/eClinical-Data-Volume-and-Diversity-Pose-Increasing-Challenges-and-Delays-According-to-the-Tufts-Center-for-the-Study-of-Drug-Development.html